Women’s Health Clinical Trials and Research

The PPD™ clinical research business of Thermo Fisher Scientific has a deep understanding of the regulatory drivers, treatment landscape, unmet needs and recruitment strategies across the spectrum of women’s health indications.

Our experience in conducting Phase I-IV and consumer health women’s health studies includes thousands of patients and hundreds of sites across a range of indications with expertise from single-site, dose-exploration studies to multinational outcomes studies. One of our women’s health core functions is designing and conducting pregnancy registries and other studies that evaluate the safety of medicinal products when used during pregnancy.

We are committed to deploying solutions needed to mitigate potential challenges in women’s health clinical trials, including competition for women in clinical trials and site resources, as well as competition with other therapeutic area trials and the reluctance of patients to participate in these studies. We leverage our broad-based site network, targeted training and communication strategies – all with the patient in mind.

Our women’s health team includes more than 1,000 clinical professionals, including board-certified obstetrics/gynecology physicians, reproductive toxicologists, epidemiologists, pharmacologists and nurses who bring extensive clinical trial operational expertise. We provide biopharmaceutical companies a deep understanding of the nuances of the patients’ care journey, their physicians and the practice settings where they seek care.

Global presence, local clinical trial experts

Our broad-ranging experience in women’s health clinical trials allows us to leverage our relationships with sites, principal investigators and key opinion leaders (KOLs) and includes recent relevant clinical trial and direct consumer health experience.

  • Data-driven approach: We provide a deep dive into the treatment landscape, including the competitive research landscape, enrollment rates and prescribing and market access data.
  • Feasibility analysis: Includes outreach to sites in a blinded fashion to assess their interest, availability of subjects that meet key inclusion/exclusion criteria, known barriers to enrolling a study and other information that could impact study enrollment and conduct.
  • Therapeutic area trainings: Development of training across multiple indications, such as menopause, osteoporosis, vaginitis, HPV-related dysplasias, urinary incontinence, high-risk obstetrics and infertility by our medical and scientific strategy experts. Training is geared toward clinical and project team members in general medicine and women’s health to maintain a cadre of trained operational resources.
  • In-depth relationships with experienced sites: Globally experienced operational and clinical teams have key relationships in multiple women’s health therapeutic areas.
  • Patient-centered approach: Incorporates the patient voice in study design, patient outcomes, barriers to participation in clinical trials and innovative use of digital platforms to bring clinical trials “closer to patients.”

Our experience in women’s health clinical trials

0 +

Studies in women’s health

0 +

Studies in breast cancer

0 +


0 +



Women’s health engagements by Evidera

Women’s health indications

  • Female contraception
  • Endometriosis
  • Uterine fibroids
  • Cervical Intraepithelial Neoplasia (CIN)
  • Women Infertility
  • Menopausal Disorders
  • Pregnancy complications
  • Preeclampsia
  • Premature Ovarian Failure
  • Polycystic Ovarian Syndrome (PCOS)
  • Female Sexual Dysfunction
  • Premature Labor (Tocolysis)
  • Atrophic Vaginitis (Vaginal Atrophy/ -Vulvovaginal Atrophy/ Urogenital Atrophy)
  • Post-Partum Depression (Maternal Depression/ Postnatal Depression)
  • Vasomotor Symptoms of Menopause (Hot Flashes)

Areas of expertise

  • Pregnancy Complications
  • Osteoporosis
  • HPV related Cervical and Genital Dysplasia
  • VVC/RVVC (Vulvovaginal Candidiasis)
  • OAB (Overactive Bladder)
  • Dysmenorrhea
  • Leiomyoma (Uterine Fibroids)
  • Preterm Labor
  • PCOS (Polycystic Ovarian Syndrome)
  • Stress Urinary Incontinence

Advancing women’s health studies in peri- and post-approval settings

Through Evidera, our peri- and post-approval business, we bring biopharmaceutical companies significant experience in key areas of women’s health, including endometriosis, uterine fibroids, breast cancer, complications related to pregnancy and many others. We have completed 92 women’s health engagements in the past five years with 7% of our real-world experience in women’s health, which includes retrospective data analytics and non-interventional/observational studies, such as pregnancy registries.

Evidera’s collaborations with our partners in women’s health have resulted in 30+ peer-reviewed publications, with papers appearing in journals such as the Journal of Allergy and Clinical Immunology, the American Journal of Obstetrics and Gynecology, BMC Pregnancy and Childbirth and many others.


“It is an exciting time for women’s health product development. Our corporate focus on women’s health is evident in our investment in expertise, site networks, recruitment capabilities and patient-centric digital solutions. Together, they underscore our commitment to addressing unmet therapeutic needs in women’s health.”

Additional women’s health clinical research resources

If you’re looking to move your product development forward, we can help.